Skip to content

Clinical efficacy analysis of diquafosol sodium eye drops combined with meibomian gland massage in the treatment of dry eye with mucin abnormalities

Clinical efficacy analysis of diquafosol sodium eye drops combined with meibomian gland massage in the treatment of dry eye with mucin abnormalities

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066093
Enrollment
Unknown
Registered
2022-11-24
Start date
2022-11-24
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucin abnormalities dry eyes

Interventions

Diquafosol sodium group:Meibomian gland massage + Diquafosol sodium eye drops are dotted 6 times a day, with meibomian gland massage, once a week
Polyethylene glycol group:Meibomian gland massage + Polyethylene glycol eye drops are applied 4 times a day with meibomian gland massage, once a week

Sponsors

General Hospital of the Northern Theater of the People's Liberation Army Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) The age of the patient is over 18 years old, male or female. (2) Patients diagnosed with mucin abnormal dry eye according to the 2020 Chinese dry eye expert consensus. (3) No history of use of diquafosol sodium in the past 1 week. (4) Total treatment time> 6 months. Each patient was studied with one eye, and if both eyes met the inclusion criteria, the right eye was selected as the study eye. (5) Those who have not received other dry eye related treatment within 1 month before coming to our outpatient clinic. (6) Fully informed, willing to sign informed consent and complete visits. Those who do not suffer from mental and psychological diseases, and can cooperate with ophthalmic examinations and complete follow-up.

Exclusion criteria

Exclusion criteria: (1) Patients with acute infection or inflammatory lesions on the ocular surface. (2) Patients with a history of previous ocular laser, surgery, or trauma. (3) Patients with incomplete eyelid closure, conjunctival relaxation, ectropion, blepharospasm. (4) Those who are under the age of 18 or over 70 years old, suffer from mental or mental illness, and are unable to cooperate. (5) Pregnant or lactating women. (6) Drugs that affect ocular surface function have been applied within half a year. (7) Patients with strabismus and amblyopia. (8) Patients with other refractive medium diseases. (9) Patients with severe systemic diseases and immunocompromised.

Design outcomes

Primary

MeasureTime frame
Time to tear film rupture;

Secondary

MeasureTime frame
Corneal conjunctival fluorescence staining;Ocular surface disease index;

Countries

China

Contacts

Public ContactYingxin Chen

Department of Ophthalmology, Northern Theater General Hospital of the Chinese People's Liberation Army

cyx156@163.com17790993588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026